Ascension | Sacred Heart Pensacola Oncology

Research site

About

Yazan Alsayed, M.D.; Alexander Brown, M.D.; Ranjith Dissanayake, M.D.; Dany El-Sayah, M.D.; Mose Hayes, M.D.; James Watkins, M.D.; Zachary Wright, M.D., F.A.C.P.

Location

1545 Airport Boulevard Ste 3000, Pensacola, Florida, United States of America

Website

https://healthcare.ascension.org/locations/florida/flpen/pensacola-ascension-sacred-heart-cancer-center/clinical-trials

Site insights

Top conditions

Top treatments

Pembrolizumab

Bevacizumab

Lenalidomide

Nivolumab

Paclitaxel

Sacituzumab

Carboplatin

Olaparib

Topotecan

Zanubrutinib

Parent organization

This site is a part of Ascension

Data sourced from clinicaltrials.gov

Active trials

6 of 32 total trials

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma (MAHOGANY)

The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\^2) in participants with...

Enrolling

Relapsed/Refractory Follicular Lymphoma

Marginal Zone Lymphoma

Drug: Rituximab

Drug: Lenalidomide

Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma. (MAGNIFY)

Follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL) are distinct histologic types of B-cell NHL. Lenalidomide is a...

Active, not recruiting

Lymphoma, Non-Hodgkin

Drug: Rituximab

Drug: Lenalidomide

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment o...

Enrolling

Recurrent Lung Non-Small Cell Carcinoma

Stage IV Lung Cancer AJCC v8

Biological: Pembrolizumab

Biological: Ramucirumab

Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma

This is a clinical study to compare the efficacy and safety of HBI-8000 combined with nivolumab to Placebo combined with nivolumab in patients with u...

Active, not recruiting

Progressive Brain Metastasis

Unresectable or Metastatic Melanoma

Drug: Placebo in combination with nivolumab

Drug: HBI-8000 in combination with nivolumab

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63)

The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surg...

Enrolling

Triple Negative Breast Cancer

Drug: Capecitabine

Drug: Sacituzumab govitecan-hziy (SG)

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-03)

The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of phy...

Enrolling

Triple Negative Breast Cancer

PD-L1 Negative

Drug: Sacituzumab Govitecan-hziy

Drug: Paclitaxel